Olivier Michielin
Overview
Explore the profile of Olivier Michielin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
16651
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brunner L, Nicolet A, Peytremann-Bridevaux I, Marti J, Bulliard J, Righi L, et al.
BMC Cancer
. 2025 Mar;
25(1):477.
PMID: 40087645
Background: The COVID-19 pandemic exerted unprecedented pressure on healthcare systems worldwide, leading governments and hospitals to postpone elective procedures to prioritize care for COVID-19 patients. Cancer patients, who often require...
2.
Mo J, Zaremba A, Inderjeeth A, El Zeinaty P, Li A, Wicky A, et al.
Eur J Cancer
. 2025 Jan;
217:115254.
PMID: 39874912
Aim: Merkel Cell Carcinoma (MCC) is a rare skin cancer with a rising incidence worldwide. Anti-programmed death-1/ligand-1 (anti-PD-(L)1) therapies are effective for the treatment of advanced MCC. This study examines...
3.
Semilietof A, Stefanidis E, Gray-Gaillard E, Pujol J, DEsposito A, Reichenbach P, et al.
J Immunother Cancer
. 2025 Jan;
12(12.
PMID: 39794936
Background: The adoptive cell transfer (ACT) of T cell receptor (TCR)-engineered T cells targeting the HLA-A2-restricted epitope NY-ESO-1 (A2/NY) has yielded important clinical responses against several cancers. A variety of...
4.
Dimitriou F, Orloff M, Koch Hein E, Cheng P, Hughes I, Simeone E, et al.
Eur J Cancer
. 2024 Dec;
214:115161.
PMID: 39647344
Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to...
5.
Hanahan D, Michielin O, Pittet M
Nat Rev Cancer
. 2024 Oct;
25(1):41-58.
PMID: 39448877
Tumorigenesis embodies the formation of a heterotypic tumour microenvironment (TME) that, among its many functions, enables the evasion of T cell-mediated immune responses. Remarkably, most TME cell types, including cancer...
6.
Chiffelle J, Barras D, Petremand R, Orcurto A, Bobisse S, Arnaud M, et al.
Immunity
. 2024 Sep;
57(10):2466-2482.e12.
PMID: 39276771
Adoptive cell therapy (ACT) using in vitro expanded tumor-infiltrating lymphocytes (TILs) has inconsistent clinical responses. To better understand determinants of therapeutic success, we tracked TIL clonotypes from baseline tumors to...
7.
Dimitriou F, Cheng P, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, et al.
Nat Cancer
. 2024 Aug;
5(9):1390-1408.
PMID: 39210005
Immune checkpoint inhibitors are standard-of-care for the treatment of advanced melanoma, but their use is limited by immune-related adverse events. Proteomic analyses and multiplex cytokine and chemokine assays from serum...
8.
Bartels M, Chibaudel B, Dienstmann R, Lehtio J, Piccolo A, Michielin O, et al.
Cancers (Basel)
. 2024 Aug;
16(16).
PMID: 39199658
The increasing volume of information for cancer care, and the evolution of molecularly guided therapies, have increased the need for molecular tumor boards (MTBs), which can integrate such data into...
9.
Williams H, Frei A, Koessler T, Berger M, Dawson H, Michielin O, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):178.
PMID: 39138341
Enabling the examination of cell-cell relationships in tissue, spatially resolved omics technologies have revolutionised our perspectives on cancer biology. Clinically, the development of immune checkpoint inhibitors (ICI) has advanced cancer...
10.
Hong A, Piva M, Liu S, Hugo W, Lomeli S, Zoete V, et al.
Cancer Discov
. 2024 Jul;
14(7):1357.
PMID: 38946326
No abstract available.